Clinicians Use Low Platelet Thresholds for Procedures in Refractory Thrombocytopenia

Navigating Procedural Risks in the Refractory Thrombocytopenic Patient

Managing critically ill patients with severe thrombocytopenia requires a delicate balance between the necessity of invasive access and the risk of life-threatening hemorrhage. While clinical guidelines provide frameworks for many hematologic and cardiovascular conditions, they often emphasize that expert judgment must adapt to individual patient circumstances [1, 2]. In the intensive care unit, platelet refractoriness, defined as a consistently poor corrected count increment (a calculation that adjusts the post-transfusion platelet rise for the patient's body surface area and the number of platelets administered), complicates this balance [3]. Supportive care remains the cornerstone for patients with sepsis or bone marrow failure, yet specific evidence for procedural safety in the setting of refractory counts remains sparse [4, 5, 6]. A recent survey of 110 intensive care clinicians found that 60% of practitioners chose a platelet transfusion threshold below 20,000/mm3 for central venous catheter placement when standard targets were unreachable, highlighting a significant gap between real-world practice and formal recommendations [7].

Surveying Practice in the Oncologic Intensive Care Unit

Clinicians in oncologic intensive care settings frequently encounter patients whose platelet counts remain profoundly low despite aggressive transfusion, a state known as refractory thrombocytopenia. To characterize how frontline providers navigate these high-stakes scenarios, researchers conducted a cross-sectional web-based survey of 110 intensive care unit clinicians. The study focused on a particularly challenging clinical void: the management of patients with counts below 5,000/mm3. Currently, no formal guideline recommendations exist for performing invasive procedures with a low bleeding risk in this specific population. This lack of standardized protocol forces practitioners to rely on institutional experience and individual clinical judgment when the need for central venous access or hemodialysis arises in the setting of profound marrow failure or consumption. The survey achieved a response rate of 59%, with 65 out of 110 clinicians completing the assessment. The participant pool represented a relatively young cohort of practitioners, with a median age of 36 years and an interquartile range of 31 to 43 years. Demographic data showed that 63% of the survey participants were female. By capturing the perspectives of these providers, the study aimed to define the specific platelet transfusion thresholds and procedural strategies employed when treating patients with counts below the 5,000/mm3 mark, a population that frequently requires life-sustaining interventions despite their profound hematologic instability.

Threshold Divergence and Procedural Techniques

The survey results highlight a notable lack of consensus regarding the minimum platelet count required for central venous catheter placement in the setting of refractory thrombocytopenia. Specifically, 60% of clinicians chose a platelet transfusion threshold of less than 20,000/mm3 for the procedure, while the remaining 40% of clinicians chose a threshold of 20,000/mm3 or higher. This divergence suggests that a majority of practitioners are comfortable operating at levels significantly lower than those traditionally recommended in broader clinical guidelines, reflecting a shift toward more permissive procedural thresholds in the oncologic intensive care unit. Beyond the transfusion threshold itself, the study identified specific technical preferences intended to mitigate bleeding risks during these high-risk interventions. A significant majority of practitioners, 74%, reported transfusing one unit of platelets while performing the procedure under ultrasound guidance. This real-time visualization is often paired with a specific anatomical preference; the internal jugular vein was the preferred site for 63% of clinicians surveyed, likely due to its compressibility and ease of ultrasound access compared to the subclavian route. These management strategies were not limited to central venous access, as the researchers found that similar strategies and platelet thresholds were employed for hemodialysis catheter placement. In addition to platelet management, clinicians frequently utilized pharmacological adjuncts to support hemostasis. Specifically, desmopressin was administered by 55% of clinicians before hemodialysis catheter placement. Desmopressin is a synthetic analogue of vasopressin that stimulates the release of von Willebrand factor from endothelial cells, which helps platelets adhere to vessel walls, providing an additional therapeutic layer for patients who remain refractory to standard platelet transfusions.

Experience Levels and Clinical Outcomes

Clinical experience appears to be a primary driver of the chosen platelet transfusion threshold for invasive procedures. The study found that Critical Care Medicine attendings and more experienced clinicians favored higher platelet thresholds, demonstrating a more conservative approach to procedural safety (P = .015). In contrast, lower thresholds were used frequently by Fellows, Advanced Practice Providers, and clinicians with 5 years or less of experience in the intensive care unit. This trend toward more permissive thresholds was also observed among practitioners who had performed fewer than 50 central venous catheter placements. These findings suggest that while senior clinicians may adhere more closely to traditional, higher-threshold guidelines, younger or more specialized staff are increasingly comfortable managing patients at lower platelet levels, perhaps due to increased proficiency with bedside ultrasound. Clinical outcomes reported by the survey participants support the feasibility of these lower thresholds in the oncologic intensive care unit. Specifically, 37% of clinicians reported that patients with platelet counts below 20,000/mm3 undergoing line placement never required a post-procedure transfusion for bleeding. This observation indicates that a substantial portion of these high-risk procedures can be completed without immediate hemorrhagic complications, even when platelet counts are severely depressed. Overall, the data show that intensive care unit clinicians are performing procedures at platelet thresholds below 20,000/mm3 safely and comfortably, highlighting a distinct gap between current restrictive guideline recommendations and real-world clinical practice. This discrepancy underscores the need for further prospective evidence to guide the management of invasive procedures in patients with refractory thrombocytopenia.

References

1. Patterson TF, Thompson GR, Denning DW, et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases. 2016. doi:10.1093/cid/ciw326

2. Members AF, Baumgartner H, Bonhoeffer P, et al. ESC Guidelines for the management of grown-up congenital heart disease (new version 2010): The Task Force on the Management of Grown-up Congenital Heart Disease of the European Society of Cardiology (ESC). European Heart Journal. 2010. doi:10.1093/eurheartj/ehq249

3. Baarle FLF, Weerdt E, Velden WJFM, et al. Predictors of the corrected count increment after platelet transfusion, a secondary analysis of the PACER randomized controlled trial. American journal of hematology/oncology. 2023. doi:10.1002/ajh.27053

4. Rhodes A, Evans L, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Critical Care Medicine. 2017. doi:10.1097/ccm.0000000000002255

5. Makris M, Veen JJV, Tait CR, Mumford A, Laffan M. Guideline on the management of bleeding in patients on antithrombotic agents. British Journal of Haematology. 2012. doi:10.1111/bjh.12107

6. Kulasekararaj A, Cavenagh J, Dokal I, et al. Guidelines for the diagnosis and management of adult aplastic anaemia: A British Society for Haematology Guideline. British Journal of Haematology. 2024. doi:10.1111/bjh.19236

7. Dulu AO, Chawla S, Onkaramurthy NJ, Zhang H, Pastores SM. Practice Variation for Platelet Transfusion in Patients with Severe Refractory Thrombocytopenia: A Survey of Critical Care Practitioners.. Journal of intensive care medicine. 2026. doi:10.1177/08850666261442460